Friday, July 19, 2024
HomeTrending NewsZycov-D Covid-19 Vaccine: India’s DNA based vaccine gets approval

Zycov-D Covid-19 Vaccine: India’s DNA based vaccine gets approval

ZyCov-D is the world’s first plasmid-based DNA COVID-19 vaccine developed by Cedilla Healthcare, an Indian pharmaceutical company. The vaccine is developed with the assistance of the Biotechnology Industry Research Assistance Council in India. The vaccine is developed to deal with the rising COVID-19 cases and is also approved for emergency usage. 

ZyCov-D is a Plasmid DNA vaccine which when given, produces the increase of protein of the SARS-CoV-2 virus and brings out an immune response immediate by the cellular and immune arms of the human body, which plays a very important role in protection from covid-19 disease and even in viral clearance.

ZyCoV-D will be jabbed in three doses. Apart from adults, it will be given to children with the age limit of 12-18 years in an emergency. The usage of this vaccine is done with intradermal injection.

source = yandex

The DNA cellular inclusion platform is a stimulating concept has been around for a few time as a method of delivering genetically built DNA into the body to stimulate the manufacture of target proteins – against that the body then mounts associate in Nursing immunologic response.

After the approval, the human trials for Phase I and II were approved. Phase I trials of the vaccine started on 15 July 2020 and went on until October 2020. The vaccine was tested on 48 healthy candidates from the age 18–55 range, with 28 days of a gap in-between each of 3 doses. 

This might be the first time that the plasmid DNA vaccine, which is technologically advanced and has been successfully developed which is for human use. It’s very adaptive because of rapid plug and plays and easily deal with mutations in the virus. The company might manufacture about 10-12 crores of vaccine every single year.

On 1 July 2021, Cadila Healthcare applied to the Drugs Controller General of India (DCGI) in need of the approval for Restricted Use in Emergency Situation of the vaccine Zycov-D. On 20 August 2021, the Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO) recommended that the DCGI approve on the same day.

The ZyCoV-D, the world’s first Plasmid DNA Vaccine for COVID-19, of Zydus Cadila today announced the vaccine had received the Emergency Use Authorization (EUA) from the Drug Controller General of India.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments